Smithbridge Asset Management Inc. DE Has $539,000 Stock Position in LifeStance Health Group, Inc. $LFST

Smithbridge Asset Management Inc. DE lowered its position in LifeStance Health Group, Inc. (NASDAQ:LFST) by 50.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 84,542 shares of the company’s stock after selling 84,542 shares during the quarter. Smithbridge Asset Management Inc. DE’s holdings in LifeStance Health Group were worth $539,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Larson Financial Group LLC increased its position in shares of LifeStance Health Group by 19,952.6% during the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after purchasing an additional 3,791 shares during the period. Bayesian Capital Management LP bought a new position in LifeStance Health Group in the second quarter worth $52,000. Krane Funds Advisors LLC bought a new position in LifeStance Health Group in the fourth quarter worth $71,000. Cibc World Markets Corp bought a new position in LifeStance Health Group in the fourth quarter worth $77,000. Finally, Qtron Investments LLC acquired a new stake in LifeStance Health Group during the fourth quarter worth $83,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

Analyst Upgrades and Downgrades

LFST has been the topic of several analyst reports. Barclays boosted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a report on Friday, March 6th. Jefferies Financial Group upgraded shares of LifeStance Health Group to a “strong-buy” rating in a research report on Thursday, March 12th. Wall Street Zen cut shares of LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 13th. BTIG Research upped their target price on shares of LifeStance Health Group from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. increased their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.75.

LifeStance Health Group Stock Performance

Shares of NASDAQ:LFST opened at $11.27 on Friday. The business’s fifty day moving average price is $8.24 and its two-hundred day moving average price is $7.37. LifeStance Health Group, Inc. has a fifty-two week low of $3.74 and a fifty-two week high of $11.62. The stock has a market capitalization of $4.37 billion, a price-to-earnings ratio of 187.83 and a beta of 1.12. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.48 and a quick ratio of 1.48.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. LifeStance Health Group had a return on equity of 1.56% and a net margin of 1.55%.The company had revenue of $403.48 million during the quarter, compared to analysts’ expectations of $387.46 million. LifeStance Health Group’s revenue was up 21.2% on a year-over-year basis. As a group, analysts predict that LifeStance Health Group, Inc. will post 0.12 EPS for the current fiscal year.

Insider Buying and Selling

In other LifeStance Health Group news, Director Eric Shuey sold 243,362 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the sale, the director directly owned 867,562 shares of the company’s stock, valued at approximately $6,957,847.24. This represents a 21.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Darren M. Black sold 5,899,661 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the sale, the director directly owned 23,310,115 shares of the company’s stock, valued at approximately $186,947,122.30. The trade was a 20.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 7,762,394 shares of company stock worth $64,107,859 in the last quarter. 3.20% of the stock is owned by corporate insiders.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.